Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy

Jayaprakash Sahoo, Sadishkumar Kamalanathan, Muthupillai Vivekanandan, Rathinam Palamalai SwaminathanJournal of Pharmacology and Pharmacotherapeutics 2015 6(3):172-174Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of anti-diabetic drugs. They control both fasting and postprandial hyperglycemia by inhibiting degradation of incretin hormones, such as, glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Sitagliptin is the first DPP-4 inhibitor to be marketed in India. In addition to its glucose lowering effect, it also suppresses immunity resulting in various infections in a diabetes patient. Here, we describe the simultaneous development of two infections (acalculous pyelonephritis and cholecystitis) in a postmenopausal female patient, well-controlled on sitagliptin-based anti-diabetic therapy.

Source: Journal of Pharmacology and Pharmacotherapeutics - August 4, 2015 Category: Drugs & Pharmacology Authors: Jayaprakash SahooSadishkumar KamalanathanMuthupillai VivekanandanRathinam Palamalai Swaminathan Source Type: research